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Aims:Obesity is associatedwith progression of chronic kidney disease (CKD). Treatmentwith bardoxolonemethyl in a
multinationalphase3 trial, BardoxoloneMethylEvaluation inPatientswithChronicKidneyDiseaseandType2Diabetes
(BEACON), resulted in increases in estimated glomerular ﬁltration rate (eGFR) with concurrent reductions in body
weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolonemethyl.
Methods: Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to b30 mL/min/1.73m2) were ran-
domized 1:1 to receive once-daily oral dose of bardoxolone methyl (20 mg) or placebo.
Results: BEACON enrolled 2185 patients. Patients randomized to bardoxolonemethyl experienced signiﬁcant reductions
inbodyweight frombaseline relative topatients randomized toplacebo (−5.7kg;95%CI:−6.0 to−5.3kg;pb 0.001). In
patients randomized to bardoxolonemethyl, rate andmagnitude of bodyweight losswere proportional to baseline BMI.
Bardoxolone methyl resulted in signiﬁcant reductions in waist circumference and improved glycemic control.
Conclusions: Bardoxolone methyl resulted in signiﬁcant weight loss in a generally obese patient population with T2DM
and stage 4 CKD, with themagnitude and rate dependent on baseline BMI.
© 2018 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Obesity increases the risk for type 2 diabetes, hypertension, dyslipid-
emia, and cardiovascular disease, as well as progressive chronic kidney
disease.1,2 Obesity is characterized by changes in adipose tissue including
the deposition of fat, enlargement of adipocytes, and a pro-inﬂammatory
phenotype that leads to the development of insulin resistance and meta-
bolic syndrome.3–5
Bardoxolone methyl and related analogs have been shown to improve
glycemic control, decrease lipid accumulation, and reduce inﬂammation in
multiple animalmodels of diabetes and obesity,6–9while also improving kid-
ney function and preventing structural injury in models of kidney
disease.10–13 Through activation of nuclear factor erythroid-derived 2-
related factor 2 (Nrf2) and inhibition of nuclear factor kappa-light-chain-
enhancer of activated B-cells (NF-κB), bardoxolone methyl up-regulates the
antioxidant response and suppresses pro-inﬂammatory signaling to reduce
oxidative stress and inﬂammation and promote mitochondrial function.14,15
Bardoxolonemethyl has also been studied in at least seven clinical tri-
als enrolling approximately 2600 patients with type 2 diabetes (T2DM)
and CKD. Improvements in kidney function, assessed using measured in-
ulin clearance, measured creatinine clearance, and estimated glomerular
ﬁltration rate (eGFR), have been observed consistently with bardoxolone
methyl treatment in several clinical trials.16–19 The largest of these was a
multinational, randomized, double-blind, placebo-controlled phase 3 out-
comes trial, which enrolled 2185 patients with T2DM and CKD stage 4
[Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease
and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)].18 The
BEACON trial was terminated early because of safety concerns, largely
driven by a signiﬁcant increase in heart failure events within the ﬁrst four
weeksof exposure. Patients randomized tobardoxolonemethyl experienced
signiﬁcantly improved kidney function. Lower serum creatinine concentra-
tions (corresponding to higher eGFRs), along with lower serum concentra-
tions of urea nitrogen, uric acid, and phosphorus were observed. In concert
with improved kidney function, reductions in body weight were also ob-
served in bardoxolonemethyl-treated patients. Given that serum creatinine
concentration depends on its clearance aswell as its generation as a function
of skeletalmusclemass20 and to address the question as towhether the ob-
served decrease in serum creatinine was related to improved GFR versus a
loss ofmusclemass,we performedpost-hoc analyses to further characterize
reductions in body weight induced by bardoxolone methyl treatment.2. Materials and methods
2.1. Study design
The BEACON trial (NCT01351675) was a phase 3, randomized,
double-blind, parallel-group, international, multicenter trial of once-
daily administration of bardoxolone methyl (20 mg), as comparedwith placebo. Previous publications describe the BEACON trial design
in detail.18,21 The study protocol was approved by Institutional Review
Boards or Ethics Committees at participating sites and all patients pro-
vided written informed consent.
BEACON enrolled adults with type 2 diabetes mellitus and stage 4 CKD,
corresponding to an eGFR of 15 to b30 mL/min/1.73m2. Patients were ran-
domized1:1 to once-daily administrationof bardoxolonemethyl or placebo.
Patients received background conventional therapy that included inhibitors
of the renin–angiotensin–aldosterone system, insulin or other hypoglycemic
agents, and, when appropriate, other cardiovascular medications.
Estimated GFR was calculated using serum creatinine and the 4-
variable Modiﬁcation of Diet in Renal Disease (MDRD) Study equation.
Estimated GFR and vital signs (including body weight and Quételet's
(body mass) index (BMI)) were assessed every 4 weeks through
Week 12, followed by assessments every 8 weeks thereafter. Waist cir-
cumference andhemoglobinA1c (HbA1c)were assessed every 24weeks.
A subset of the patients (n= 174, 8%) consented to additional 24-hour
urine collections at baseline and Week 4; to assess whether the weight
loss was derived from muscle mass or adipose tissue, we examined
changes in urinary creatinine excretion over 24 h.
Theprimary composite endpoint of the trialwas the time-to-ﬁrst event in
the composite outcome deﬁned as end-stage renal disease (ESRD; need
formaintenancedialysis, kidney transplantation, or renaldeath)or cardiovas-
cular death. Secondary efﬁcacy outcomes included the change in eGFR, time-
to-ﬁrst hospitalization forheart failureordeathdue toheart failure, and time-
to-ﬁrst event of a composite consisting of non-fatal myocardial infarction,
non-fatal stroke, hospitalization for heart failure, or cardiovascular death.
2.2. Statistical analysis
We analyzed the BEACON population using summary statistics to
compare changes in body weight, waist circumference, and HbA1c in pa-
tients randomized to bardoxolone methyl or placebo in accordance with
the intention-to-treat principle. One-sample (paired) t-tests were used
for comparing mean changes to zero and two-sample t-tests were used
to compare the difference in means between bardoxolone methyl and
placebo groups. Longitudinal analyses of body weight were also used to
comparemean changes in bodyweight between the bardoxolonemethyl
and placebo groups. As previously described, mixed-effects regression
used post-baseline body weight as the response variable; treatment
group, time, the interaction of treatment group with time, interaction of
baseline bodyweight with time; and continuous covariates (bodyweight
at baseline, baseline eGFR and urinary albumin-to-creatinine ratio).18
3. Results
As previously published, from June 2011 through September 2012, a
total of 2185 patients were randomized to receiving either bardoxolone
Fig. 1. Changes from baseline in body weight with bardoxolone methyl by baseline BMI.
Mean changes from baseline in body weight (kg) for patients randomised to
bardoxolone methyl stratiﬁed by baseline BMI categories using World Health
Organization (WHO) classiﬁcations: Underweight (b 18.5 kg/m2): n = 0 (0%); normal
weight (18.5 to 24.9 kg/m2): n = 78 (7%); overweight (25.0 to 29.9 kg/m2): n = 269
(24%); class I obesity (30.0 to 34.9 kg/m2): n = 334 (31%); class II obesity (35.0 to
39.9 kg/m2): n= 231 (21%); class III obesity (≥ 40.0 kg/m2): n= 175 (16%).
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describe the demographics and baseline characteristics of the patients
randomized to bardoxolonemethyl versus those randomized to placebo
in BEACON,22 which are summarized in Table 1, alongwith characteris-
tics of the 174 patients who consented to 24-hour urine collections. The
demographics and baseline characteristics for the subset of patients that
consented to additional 24-hour urine collectionswere similar to that of
the entire BEACON population and between patients randomized to
bardoxolone methyl or placebo.
3.1. Weight
The majority of patients enrolled in BEACON were overweight or
obese; 93% of patients had BMI ≥ 25.0 kg/m2 at baseline. The mean
BMI and body weights at baseline were 33.7 ± 7.1 kg/m2 and 95.1 ±
22.0 kg for patients randomized to bardoxolone methyl (n = 1088),
and 33.9±7.2 kg/m2 and95.3±21.1 kg for patients randomized to pla-
cebo (n = 1097). As previously reported, patients randomized to
bardoxolonemethyl experienced a signiﬁcant reduction in bodyweight
compared to placebo (−5.7 kg [95% CI:−6.0 to−5.3 kg]; p b 0.001).18
In patients randomized to bardoxolone methyl, the rate and magni-
tude of body weight loss were proportional to baseline BMI (Fig. 1).
Bodyweight plateaued at 32weeks in patients within theWorld Health
Organization (WHO) lean and normal BMI groups at baseline (18.5 to
24.9 kg/m2), while it continued to decline in patients who were over-
weight (25.0 to 29.9 kg/m2) or obese (≥30 kg/m2) at baseline.
3.2. Waist circumference
Bardoxolone methyl treatment signiﬁcantly decreased waist cir-
cumference relative to baseline and relative to placebo at Weeks 24
and 48 (p b 0.01; Fig. 2, panel A). Bardoxolone methyl-treated patients
had mean (±SD) decreases in waist circumference of−4.1 ± 8.0 cm
(n=622) atWeek 24 and− 6.5±9.3 cm(n=239) atWeek 48. In con-
trast, placebo-treated patients experienced minimal to no change in
waist circumference at Week 24 and Week 48 (mean ± SD -0.4 ± 8.4
(n= 717) and 0.0 ± 8.6 (n= 280) at Weeks 24 and 48, respectively).
Similar to changes in body weight, the magnitude of reductions in
waist circumference with bardoxolone methyl treatment was propor-
tional to baselineBMI; obese patients experiencedmore pronounced re-
ductions in waist circumference compared with patients who were not
obese (Fig. 2, panel B).
3.3. 24-Hour urinary excretion
As seen in Table 1, the mean baseline BMI and body weight for the
subset of patients who consented to additional 24-hour urine collectionsTable 1
Select demographics and baseline characteristics of BEACON patients.
Intent-to-treat population
Placebo
(n = 1097)
Bar
(n =
Age, yr (mean ± SD) 68.2 ± 9.4 68.9
Female (n, %) 472 (43) 462
Race (n, %)
Caucasian 848 (77) 846
Black 176 (16) 185
Other 73 (7) 57 (
Weight, kg (mean ± SD) 95.3 ± 21.1 95.1
BMI, kg/m2 (mean ± SD) 33.9 ± 7.2 33.7
HbA1c, % (mean ± SD) 7.10 ± 1.17 7.15
Serum creatinine, mg/dl (mean ± SD) 2.7 ± 0.6 2.7
eGFR, ml/min/1.73 m2 (mean ± SD) 22.5 ± 4.6 22.4
UACR, mg/g (geometric mean) 221 210
Insulin (n, %) 677 (62) 667
Partially Reproduced from: Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidnewere similar to that of the entire BEACONpopulation. Accordingly, signif-
icant reductions in bodyweightwere observed in patients randomized to
bardoxolone methyl at Week 4 (mean ± SD=−0.7 ± 2.0 kg; p= 0.03
for bardoxolone methyl versus placebo). Conversely, mean (±SD) 24-
hour urinary creatinine excretion with bardoxolone methyl was un-
changed from baseline at Week 4 (1134 ± 394 mg versus 1191 ±
339 mg at baseline; n = 61) and was not signiﬁcantly different from
changes with placebo (Table 2; p= 0.33).
3.4. Hemoglobin A1c
MeanbaselineHbA1cwas 7.15±1.27% and 7.10±1.17% for patients
randomized to bardoxolone methyl and placebo, respectively.
Bardoxolone methyl treatment signiﬁcantly decreased HbA1c relative
to baseline at Week 24 (−0.12 ± 1.04; p = 0.0033) and at Week 48
(−0.17 ± 1.13%; p = 0.026; Table 3); between group differences
were also statistically signiﬁcant at Week 24 and Week 48 (−0.13 ±
1.01, p= 0.023 and− 0.25 ± 1.13, p= 0.014, respectively), as HbA1cPatients with 24-hr urine collections
doxolone methyl
1088)
Placebo
(n = 87)
Bardoxolone methyl
(n = 87)
± 9.7 67.2 ± 10.3 67.8 ± 10.4
(42) 42 (48) 37 (43)
(78) 61 (70) 68 (78)
(17) 14 (16) 11 (13)
5) 12 (14) 8 (9)
± 22.0 95.9 ± 24.1 94.3 ± 20.5
± 7.1 34.3 ± 7.9 33.7 ± 6.4
± 1.27 6.97 ± 0.97 7.36 ± 1.54
± 0.6 2.8 (0.6) 2.7 (0.5)
± 4.3 21.8 (4.2) 22.7 (4.3)
221 210
(61) 48 (55) 53 (61)
y Disease. De Zeeuw et al. N Engl. J. Med. 369:2495, Copyright © 2013.18
Fig. 2.Changes from baseline inwaist circumference. Left. Mean changes (±SEM) from baseline inwaist circumference (cm) for patients randomized to bardoxolonemethyl or placebo in
BEACON. * p b 0.001 versus placebo. Right. Mean changes (± SEM) from baseline in waist circumference for patients randomized to bardoxolonemethyl stratiﬁed by non-obese baseline
BMI (b 30 kg/m2) versus obese baseline BMI (≥ 30 kg/m2) categories.
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tantly, reductions in HbA1c induced by bardoxolonemethyl were driven
by results in patients with abnormal HbA1c (N7.0%) at baseline; mean
changes in HbA1c after 48 weeks of bardoxolone methyl treatment
were−0.53 ± 1.47% in patients with baseline HbA1c N 7.0% (Table 3).
4. Discussion
Bardoxolone methyl treatment resulted in signiﬁcant reductions in
body weight in a generally overweight and obese patient population
with T2DM and stage 4 CKD. The magnitude and rate of weight reduc-
tions were more pronounced in patients with higher baseline BMI.
The loss in body weight was accompanied by a signiﬁcant reduction in
waist circumference, with declines proportional to both baseline body
weight and BMI. Moreover, bardoxolone methyl signiﬁcantly improved
glycemic control with results driven by patients with HbA1c above clin-
ical practice guideline recommended targets at baseline. Finally, in a
subset of patients who provided timed urine collections, there was no
reduction in 24-hour urinary creatinine excretion, suggesting that the
loss in body weight was not due to muscle wasting, but rather to loss
of adipose tissue, ﬁndings consistent with the changes in waist circum-
ference and glycemic control observed in the larger trial population. It is
noteworthy that the BEACON trial protocol neither mandated nor rec-
ommended any particular diet, exercise or other lifestyle modiﬁcations
that might account for the observed weight loss.
The trajectory and proﬁle of increases in eGFR following treatment
with bardoxolone methyl differ from that of the reductions in body
weight; unlike mean changes from baseline in body weight, meanTable 2
24-Hour urinary creatinine excretion over time and change from baseline.
Urinary creatinine (mg/24 h) Placebo
N = 65
Bardoxolone methyl
N = 61
Baseline 1159 ± 471 1191 ± 339
Week 4 1155 ± 457 1134 ± 394
Change from Baseline −4 ± 327 −57 ± 280
Data are mean values ± SD and only include patients with baseline and Week 4 urinary
creatinine values.increases in eGFR with bardoxolone methyl were apparent by Week 4
of treatment. In a Japanese trial, bardoxolone methyl signiﬁcantly in-
creased measured GFR, as assessed by inulin clearance, in patients
with T2DM and stage 3 CKD after 16 weeks of treatment compared to
placebo,19 demonstrating that bardoxolonemethyl-mediated improve-
ments in eGFR reﬂect true improvements in measured GFR.
Multiple studies in preclinical models of diabetes and obesity have
demonstrated that bardoxolone methyl and its analogs reduce fat pro-
duction and promote beta-oxidation of lipids to be used as fuel for en-
ergy production and reduced food intake.6 These effects are associated
with improved glucose tolerance and insulin sensitivity, reduced body
fat, preservation of muscle mass, and increased metabolism and energy
expenditure.6,7,23 Moreover, bardoxolone methyl has also been shown
to prevent hypothalamic inﬂammation, leptin resistance, and body
weight gain in mice fed high-fat diets.24 Although the mechanism of
the weight loss associated with bardoxolone methyl treatment in
humans is not fully understood, the prevention of leptin signaling im-
pairments, maintenance of energy homeostasis, increased lipolysis of
peripheral lipid stores, and improvements in glycemic control observed
in preclinical studies may explain the reductions in body weight ob-
served in patients with T2DM and CKD.
Strengths of this trial include a randomized design, a diverse patient
population, and high clinical relevance to patients with T2DM and CKD.
There was consistency of ﬁndings suggesting loss of adipose tissue rather
than muscle mass across multiple parameters including body weight,
waist circumference, 24-hour urinary creatinine excretion, and HbA1c.
While we hypothesized a beneﬁcial effect on body weight and metabo-
lism in bardoxolone methyl-treated patients, the trial was not designed
to examine changes in body weight, waist circumference, and glycemic
control; thus additional trials may be required to conﬁrm these ﬁndings.
Assessment of inﬂammatorymarkers in future studiesmay also elucidate
how the anti-inﬂammatory effects of bardoxolone methyl are associated
with the changes in body weight and other metabolic parameters.
While the effects on body weight and related parameters with
bardoxolone methyl are generally considered beneﬁcial in an obese
population with T2DM and CKD, weight loss may be an undesirable ef-
fect in some patients. Subgroup analyses suggest that there was very
limited loss of body weight in the small fraction of patients who were
not overweight or obese. Moreover, themagnitude of weight reduction,
trimming of waist circumference, and improvements in glycemic
Table 3
Change from baseline in hemoglobin A1c.
Observed HbA1c (%) Change from baseline (%)
Baseline Week 24 Week 48 Week 24 Week 48
All patients
Placeboa 7.10 ± 1.17
(n = 1097)
7.11 ± 1.29
(n = 721)
7.24 ± 1.44
(n = 275)
0.00 ± 0.99
(p = 0.92)
0.08 ± 1.12
(p = 0.24)
Bardoxolone methyla 7.15 ± 1.27
(n = 1088)
6.96 ± 1.30
(n = 629)
6.90 ± 1.32
(n = 236)
−0.12 ± 1.04
(p = 0.0033)
−0.17 ± 1.13
(p = 0.026)
Difference between treatment groupsb −0.13 ± 1.01
(p = 0.023)
−0.25 ± 1.13
(p = 0.014)
Baseline HbA1c N 7.0%
Placeboa 8.10 ± 0.91
(n = 501)
7.90 ± 1.21
(n = 338)
8.07 ± 1.41
(n = 137)
−0.18 ± 1.14
(p = 0.0043)
0.00 ± 1.39
(p = 1.0)
Bardoxolone methyla 8.22 ± 0.98
(n = 509)
7.76 ± 1.32
(n = 283)
7.74 ± 1.44
(n = 100)
−0.44 ± 1.29
(p b 0.001)
−0.53 ± 1.47
(p b 0.001)
Difference between treatment groupsb −0.26 ± 1.21
(p = 0.0086)
−0.53 ± 1.42
(p = 0.0051)
Baseline HbA1c ≤ 7.0%
Placeboa 6.25 ± 0.51
(n = 596)
6.42 ± 0.90
(n = 383)
6.41 ± 0.87
(n = 138)
0.16 ± 0.80
(p b 0.001)
0.16 ± 0.76
(p = 0.015)
Bardoxolone methyla 6.21 ± 0.54
(n = 579)
6.31 ± 0.83
(n = 346)
6.28 ± 0.78
(n = 136)
0.14 ± 0.69
(p b 0.001)
0.10 ± 0.70
(p = 0.084)
Difference between treatment groupsb 0.03 ± 0.75
(p = 0.60)
−0.05 ± 0.73
(p = 0.53)
Data are mean values ± SD.
a p-Values comparing values at Week 24 or Week 48 to baseline values within each treatment group.
b p-Values comparing the difference in means between the bardoxolone methyl and placebo groups.
1117G.M. Chertow et al. / Journal of Diabetes and Its Complications 32 (2018) 1113–1117control in overweight and obese patients compare favorably to other
interventions.
5. Conclusions
In summary, in patients with T2DM and stage 4 CKD, treatment with
bardoxolone methyl results in signiﬁcant loss of body weight, without
evidence of muscle wasting. Reductions in waist circumference and im-
provements in glycemic control suggest generally favorably metabolic
effects in overweight and obese persons. If the risk of symptomatic
heart failure after treatment initiation can bemitigated by dose titration,
dietary salt restriction or other strategies, bardoxolone methyl may
prove to be an effective treatment for obesity in patients with T2DM.
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